A paradoxical effect of lidocaine for the N406S mutation of SCN5A associated with Brugada syndrome

International Journal of Cardiology

Volumn 121, Issue 3, 2007, Pages 239-248

  Itoh, Hideki ^a,b   Tsuji, Keiko ^b   Sakaguchi, Tomoko ^b   Nagaoka, Iori ^b   Oka, Yuko ^b   Nakazawa, Yuko ^b   Yao, Takenori ^b   Jo, Hikari ^b   Ashihara, Takashi ^b   Ito, Makoto ^b   Horie, Minoru ^b   Imoto, Keiji ^a  

^a NATIONAL INSTITUTE FOR PHYSIOLOGICAL SCIENCES   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Brugada syndrome; Inactivation; Lidocaine; SCN5A; Sodium channel

Indexed keywords

LIDOCAINE; SODIUM CHANNEL;

ALPHA CHAIN; ARTICLE; BETA CHAIN; BRUGADA SYNDROME; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG EFFECT; GENE; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PATCH CLAMP; PRIORITY JOURNAL; SCN5A GENE; SODIUM CURRENT; WHOLE CELL;

ANTI-ARRHYTHMIA AGENTS; BRUGADA SYNDROME; COMPUTER SIMULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIDOCAINE; MALE; MARKOV CHAINS; MUSCLE PROTEINS; MUTATION, MISSENSE; PATCH-CLAMP TECHNIQUES; SODIUM CHANNELS;

EID: 34548816721     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.02.007     Document Type: Article

References (27)

1. Brugada P., and Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. J Am Coll Cardiol 20 (1992) 1391-1396
2. Priori S.G., Napolitano C., Gasparini M., et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 105 (2002) 1342-1347
3. Belhassen B., Glick A., and Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 110 (2004) 1731-1737
4. Chen Q., Kirsch G., Zhang D., et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 392 (1998) 293-295
5. Rook M.B., Bezzina Alshinawi C., Groenewegen W.A., et al. Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome. Cardiovasc Res 44 (1999) 507-517
6. Miyazaki T., Mitamura H., Miyoshi S., et al. Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol 27 (1996) 1061-1070
7. Takagi M., Doi A., Takeuchi K., and Yoshikawa J. Pilsicainide-induced marked T wave alternans and ventricular fibrillation in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 13 (2002) 837
8. Morita H., Morita S.T., Nagase S., et al. Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol 42 (2003) 1624-1631
9. Itoh H., Shimizu M., Takata S., Mabuchi H., and Imoto K. A novel missense mutation in the SCN5A gene associated with Brugada syndrome bidirectionally affecting blocking actions of antiarrhythmic drugs. J Cardiovasc Electrophysiol 16 (2005) 486-493
10. Itoh H., Horie M., Ito M., and Imoto K. Arrhythmogenesis in the short-QT syndrome associated with combined HERG channel gating defects: a simulation study. Circ J 70 (2006) 502-508
11. + channel mutation that causes both Brugada and long-QT syndrome phenotypes: a simulation study of mechanism. Circulation 105 (2002) 1208-1213
12. Wilde A.A., Antzelevitch C., Borggrefe M., et al. Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation 106 (2002) 2514-2519
13. Abriel H., Wehrens X.H.T., Benhorin J., Kerem B., and Kass R.S. Molecular pharmacology of the sodium channel mutation D1790G linked to the long-QT syndrome. Circulation 102 (2000) 921-925
14. Baroudi G., Pouliot V., Denjoy I., Guicheney P., Shrier A., and Chahine M. Novel mechanism for Brugada syndrome: defective surface localization of an SCN5A mutant (R1432G). Circ Res 88 (2001) e78-e83
15. Itoh H., Shimizu M., Mabuchi H., and Imoto K. Clinical and electrophysiological characteristics of Brugada syndrome caused by a missense mutation in the S5-pore site of SCN5A. J Cardiovasc Electrophysiol 16 (2005) 378-383
16. + channels. Circ Res 79 (1996) 103-108
17. Nuss H.B., Kambouris N.G., Marban E., Tomaselli G.F., and Balser J.R. Isoform-specific lidocaine block of sodium channels explained by differences in gating. Biophys J 78 (2000) 200-210
18. Brugada J., Brugada R., and Brugada P. Pharmacological and device approach to therapy of inherited cardiac diseases associated with cardiac arrhythmias and sudden death. J Electrocardiol 33 (2000) 41-47
19. Brugada P., Brugada R., Brugada J., and Geelen P. Use of the prophylactic implantable cardioverter defibrillator for patients with normal hearts. Am J Cardiol 83 (1999) 98D-100D
20. Antzelevitch C. The Brugada syndrome: ionic and arrhythmia mechanisms. J Cardiovasc Electrophysiol 12 (2001) 268-272
21. Yan G.X., and Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 100 (1999) 1660-1666
22. Alings M., Dekker L., Sadee A., and Wilde A. Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol 24 (2001) 1420-1422
23. Shimizu W., Matsuo K., Takagi M., et al. Body surface distribution and response to drug of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol 11 (2000) 396-404
24. Tanaka H., Kinoshita O., Uchikawa S., et al. Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome. Pacing Clin Electrophysiol 24 (2001) 1293-1294
25. Belhassen B., Viskin S., Fish R., Glick A., Setbon I., and Eldar M. Effects of electrophysiologic-guided therapy with class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 10 (1999) 1301-1312
26. Belhassen B., Glick A., and Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 110 (2004) 1731-1737
27. Tsuchiya T., Ashikaga K., Honda T., and Arita M. Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 13 (2002) 698-701